Core Insights - Quantum BioPharma Ltd. reported strong financial and operational results for Q3 2025, highlighting significant improvements in shareholder equity and reductions in liabilities [2][3][5] Financial Performance - Shareholder equity increased by 275%, rising from US$2 million to US$7.5 million [5] - Total liabilities decreased by 50%, from US$13.2 million to US$6.6 million [5][6] - The debt-to-equity ratio improved by 87%, from 6.47x to 0.89x [5] - General and Administrative expenses saw an 8% reduction, amounting to a decrease of approximately US$210,000 compared to the same quarter last year [2][6] - The current ratio improved from 0.78x to 1.41x, indicating better liquidity [5] Digital Asset Portfolio - The digital asset portfolio realized gains of US$572,000, primarily from Bitcoin investments [2][6][16] - Total digital assets reached US$5.2 million as of September 30, 2025, compared to US$0.8 million at the end of 2024 [6] Clinical Development - The company is advancing its multiple sclerosis drug, Lucid-21-302 ("Lucid-MS"), with completed Phase 1 oral toxicity studies showing no adverse effects [4][12] - A joint PET study with Massachusetts General Hospital has commenced to monitor myelin integrity in MS patients [7][16] - An agreement has been signed to prepare an IND application for Lucid-MS with the FDA [7] Product Licensing and Market Growth - Unbuzzd Wellness Inc., the licensee of Quantum's product unbuzzd, is preparing for a capital raise of up to US$5 million for a potential IPO, which will not dilute Quantum's shares [8][13][16] - Health Canada granted a Product License for Qlarity, allowing sales in Canada [8][16] Legal Matters - Quantum has filed a memorandum opposing a motion to dismiss in its lawsuit against CIBC and RBC regarding alleged stock market manipulation [9][10]